Van ECK Associates Corp Has $139.75 Million Holdings in Gilead Sciences, Inc. $GILD

Van ECK Associates Corp decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,259,022 shares of the biopharmaceutical company’s stock after selling 4,961 shares during the quarter. Van ECK Associates Corp owned approximately 0.10% of Gilead Sciences worth $139,752,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GILD. Capital International Inc. CA lifted its holdings in Gilead Sciences by 29.4% during the 3rd quarter. Capital International Inc. CA now owns 357,879 shares of the biopharmaceutical company’s stock valued at $39,725,000 after purchasing an additional 81,363 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Gilead Sciences by 4.2% in the 3rd quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock valued at $1,133,376,000 after purchasing an additional 414,454 shares during the last quarter. Fieldview Capital Management LLC bought a new stake in Gilead Sciences in the third quarter valued at about $1,908,000. WINTON GROUP Ltd increased its stake in Gilead Sciences by 47.3% in the third quarter. WINTON GROUP Ltd now owns 66,742 shares of the biopharmaceutical company’s stock valued at $7,408,000 after purchasing an additional 21,427 shares in the last quarter. Finally, Inceptionr LLC acquired a new position in Gilead Sciences in the third quarter valued at about $402,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Barclays initiated coverage on Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price target on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Daiwa Securities Group lifted their target price on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $157.62.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Jefferies initiated coverage on Gilead with a Buy rating and $180 price target, giving the stock meaningful upside from current levels and signaling renewed analyst conviction. Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence
• Positive Sentiment: Gilead’s planned acquisition of Arcellx for up to $7.8B materially expands its oncology/CAR-T-like cell therapy pipeline — a strategic growth move that supports a higher multiple for the stock if pipeline synergies materialize. Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion
• Positive Sentiment: Short interest fell ~15.7% in February to about 18.45M shares (1.5% of float) and a days-to-cover near 2.7 — reduced short pressure can support upward moves and dampen volatility on positive news. (Data summary entry)
• Neutral Sentiment: Industry report: DelveInsight projects significant expansion in the CD19 inhibitor market through 2034, which is a favorable long-term market backdrop for firms investing in B‑cell/immune-oncology programs, including Gilead’s recent dealmaking. CD19 Inhibitors Market to Witness Significant Expansion
• Neutral Sentiment: Gilead presented at the Leerink Global Healthcare Conference (transcript published) — investor events can clarify pipeline timelines and commercial plans but typically move the stock only if new guidance or data are released. Gilead Sciences, Inc. Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: The Arcellx deal carries a steep premium (~79%) and a headline price tag (~$7.8B); while strategic, the acquisition could pressure near-term capital deployment, earnings per share or leverage if funded with cash/debt — a risk investors will watch. Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion

Gilead Sciences Stock Performance

Shares of GILD opened at $148.56 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The stock has a market cap of $184.43 billion, a P/E ratio of 21.94, a P/E/G ratio of 1.92 and a beta of 0.37. The business’s 50 day moving average price is $139.23 and its 200-day moving average price is $126.30.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the firm earned $1.90 EPS. Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio is 46.68%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total value of $463,290.00. Following the sale, the chief financial officer owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. This represents a 1.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 309,280 shares of company stock worth $43,935,470 in the last three months. 0.27% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.